These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 19158312)
1. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese. Matsunaga M; Yamazaki H; Kiyotani K; Iwano S; Saruwatari J; Nakagawa K; Soyama A; Ozawa S; Sawada J; Kashiyama E; Kinoshita M; Kamataki T Drug Metab Dispos; 2009 Apr; 37(4):699-701. PubMed ID: 19158312 [TBL] [Abstract][Full Text] [Related]
2. Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity. Ishiguro A; Kubota T; Ishikawa H; Iga T Clin Chim Acta; 2004 Jun; 344(1-2):201-4. PubMed ID: 15149890 [TBL] [Abstract][Full Text] [Related]
3. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Yu A; Dong H; Lang D; Haining RL Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510 [TBL] [Abstract][Full Text] [Related]
4. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Fukuda T; Nishida Y; Imaoka S; Hiroi T; Naohara M; Funae Y; Azuma J Arch Biochem Biophys; 2000 Aug; 380(2):303-8. PubMed ID: 10933885 [TBL] [Abstract][Full Text] [Related]
5. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754 [TBL] [Abstract][Full Text] [Related]
8. Tryptamine: a possible endogenous substrate for CYP2D6. Martínez C; Agúndez JA; Gervasini G; Martín R; Benítez J Pharmacogenetics; 1997 Apr; 7(2):85-93. PubMed ID: 9170145 [TBL] [Abstract][Full Text] [Related]
9. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. Yu A; Kneller BM; Rettie AE; Haining RL J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554 [TBL] [Abstract][Full Text] [Related]
10. CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528. Kotsuma M; Tokui T; Ishizuka-Ozeki T; Honda T; Iwabuchi H; Murai T; Ikeda T; Saji H Drug Metab Dispos; 2008 Mar; 36(3):529-34. PubMed ID: 18056254 [TBL] [Abstract][Full Text] [Related]
11. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes. Li L; Pan RM; Porter TD; Jensen NS; Silber P; Russo G; Tine JA; Heim J; Ring B; Wedlund PJ Drug Metab Dispos; 2006 Aug; 34(8):1411-6. PubMed ID: 16679388 [TBL] [Abstract][Full Text] [Related]
12. Developmental changes in human liver CYP2D6 expression. Stevens JC; Marsh SA; Zaya MJ; Regina KJ; Divakaran K; Le M; Hines RN Drug Metab Dispos; 2008 Aug; 36(8):1587-93. PubMed ID: 18474679 [TBL] [Abstract][Full Text] [Related]
13. Development of a rapid and sensitive high-performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes. Rege B; March C; Sarkar MA Biomed Chromatogr; 2002 Feb; 16(1):31-40. PubMed ID: 11816009 [TBL] [Abstract][Full Text] [Related]
14. Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan. Uno Y; Uehara S; Kohara S; Murayama N; Yamazaki H Drug Metab Dispos; 2010 Sep; 38(9):1486-92. PubMed ID: 20501912 [TBL] [Abstract][Full Text] [Related]
15. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans. Casner PR J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355 [TBL] [Abstract][Full Text] [Related]
16. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888 [TBL] [Abstract][Full Text] [Related]
17. Effect of sodium ozagrel on the activity of rat CYP2D6. Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725 [TBL] [Abstract][Full Text] [Related]
18. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265 [TBL] [Abstract][Full Text] [Related]
19. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein. Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457 [TBL] [Abstract][Full Text] [Related]
20. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Toscano C; Raimundo S; Klein K; Eichelbaum M; Schwab M; Zanger UM Pharmacogenet Genomics; 2006 Oct; 16(10):767-70. PubMed ID: 17001296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]